title: Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study.
abstract: A multi-center retrospective analysis of a cohort of patients in Israel treated with any bendamustine containing regimen between 2010-2014 was performed in order to determine the incidence and predictors for infection. The Kaplan Meier Model, employing log rank analysis, was used to assess time-to-infection. The Cox Proportional Hazards model was used to analyze multivariate effects of risk and 234 patients were included in the analysis. One hundred and nine (46.6%) developed at least one infection and 33.76% had severe infections. Seventy-six (41.5%) developed bacterial infection, nine (3.8%) fungal infection and 26 (11.5%) had viral infections. Factors significantly associated with time to infection on multivariable analysis were: bendamustine-combinations [hazard ratio (HR) = 0.589 (95% CI = 0.374-0.926), p = 0.022], Hb level [HR = 0.791 (95% CI = 0.716-0.875), p < 0.0001] and ischemic heart disease [HR = 1.828 (95% CI = 1.165-2.868), p = 0.009]. Infections were associated with a higher mortality and hospitalization rate.
authors.affiliation: a Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva , Israel.|b Sackler School of Medicine , Tel-Aviv , Israel.
authors.forename: Anat
authors.initials: A
authors.lastname: Gafter-Gvili
authors.affiliation: b Sackler School of Medicine , Tel-Aviv , Israel.|c Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center , Tel Hashomer , Israel.
authors.forename: Elena
authors.initials: E
authors.lastname: Ribakovsky
authors.affiliation: b Sackler School of Medicine , Tel-Aviv , Israel.
authors.forename: Nadav
authors.initials: N
authors.lastname: Mizrahi
authors.affiliation: b Sackler School of Medicine , Tel-Aviv , Israel.|c Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center , Tel Hashomer , Israel.
authors.forename: Abraham
authors.initials: A
authors.lastname: Avigdor
authors.affiliation: d Department of Hematology , HaEmek Medical Center , Afula , Israel.
authors.forename: Ariel
authors.initials: A
authors.lastname: Aviv
authors.affiliation: a Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva , Israel.|b Sackler School of Medicine , Tel-Aviv , Israel.
authors.forename: Liat
authors.initials: L
authors.lastname: Vidal
authors.affiliation: b Sackler School of Medicine , Tel-Aviv , Israel.|e Institute of Hematology, Sourasky Medical Center , Tel Aviv , Israel.
authors.forename: Ron
authors.initials: R
authors.lastname: Ram
authors.affiliation: e Institute of Hematology, Sourasky Medical Center , Tel Aviv , Israel.
authors.forename: Chava
authors.initials: C
authors.lastname: Perry
authors.affiliation: b Sackler School of Medicine , Tel-Aviv , Israel.|e Institute of Hematology, Sourasky Medical Center , Tel Aviv , Israel.
authors.forename: Irit
authors.initials: I
authors.lastname: Avivi
authors.affiliation: b Sackler School of Medicine , Tel-Aviv , Israel.|c Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center , Tel Hashomer , Israel.
authors.forename: Meirav
authors.initials: M
authors.lastname: Kedmi
authors.affiliation: b Sackler School of Medicine , Tel-Aviv , Israel.|c Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center , Tel Hashomer , Israel.
authors.forename: Arnon
authors.initials: A
authors.lastname: Nagler
authors.affiliation: a Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva , Israel.|b Sackler School of Medicine , Tel-Aviv , Israel.
authors.forename: Pia
authors.initials: P
authors.lastname: Raanani
authors.affiliation: a Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center , Petah-Tikva , Israel.|b Sackler School of Medicine , Tel-Aviv , Israel.
authors.forename: Ronit
authors.initials: R
authors.lastname: Gurion
mesh_terms: D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride / Q000009:adverse effects* / Q000627:therapeutic use; D015415:Biomarkers; D005260:Female; D006402:Hematologic Diseases / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006760:Hospitalization; D006801:Humans; D015994:Incidence; D007239:Infections / Q000453:epidemiology* / Q000209:etiology*; D007557:Israel / Q000453:epidemiology; D008232:Lymphoproliferative Disorders / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D018906:Antineoplastic Agents, Alkylating; D015415:Biomarkers; D000069461:Bendamustine Hydrochloride
keywords: Bendamustine; infections; lymphoproliferative disorders